ABSTRACT
Introduction
In the field of obstetrics, the number of publications on prognostic models has more than tripled in the past decade, 1 which reflects an increasing interest in risk based medicine. Risk based medicine aims to provide the most appropriate care to each patient, often guided by outcome risk estimates based on individual patient characteristics, test results, or even genetic information. 2 As a result of the obesity pandemic, the incidence of gestational diabetes mellitus, notably occurring in the second or third trimester, is rising and is increasingly contributing to perinatal complications such as macrosomia, shoulder dystocia, caesarean section, and neonatal hypoglycaemia. 3 4 Moreover, long term sequelae of gestational diabetes mellitus are type 2 diabetes in mothers and obesity in their offspring. 5 6 Early diagnosis and treatment of gestational diabetes mellitus have been proven to improve pregnancy outcomes. 7 8 Some guidelines propose a population strategy for diagnosing the disorder [9] [10] [11] [12] (that is, an oral glucose tolerance test) in all pregnant women, whereas others opt for a high risk strategy, 13 which tests for gestational diabetes mellitus only in women with known risk factors. Both strategies include oral glucose tolerance tests in substantial numbers of women, most of which will lead to negative results, and therefore pose a too high burden to patients as well as health care resources. 14 
Accurate

WhAT IS AlReAdy knoWn on ThIS TopIC
Gestational diabetes mellitus is an increasingly common complication of pregnancy, and pregnancy outcomes can be improved through early screening, diagnosis, and treatment Many prognostic models estimating the risk of gestational diabetes mellitus have been developed, but an external validation and direct comparison in an independent large cohort of all published models is lacking
WhAT ThIS STudy AddS
This external validation study shows that in a direct comparison, most published prognostic models for gestational diabetes mellitus in the first trimester have an acceptable discrimination and good calibration
The best performing models in this group can be considered for implementation in routine clinical care prognostic models for the risk of patients developing gestational diabetes mellitus early in pregnancy could discriminate between high risk and low risk pregnancies, and move towards more tailored care in pregnancy. In particular, this tailored care could result in fewer women undergoing a burdensome diagnostic test (that is, women with a predicted low risk for gestational diabetes mellitus not having to undergo an oral glucose tolerance test).
Several prognostic models for gestational diabetes mellitus have been developed. However, these prognostic models are not commonly used in routine clinical care nor are they recommended by current guidelines. This might be due to the fact that external validation of these prognostic models are scarce, [15] [16] [17] [18] let alone that all these models have been directly evaluated and compared on the basis of their predictive accuracy in one independent cohort by independent investigators. To acquire a fair comparison of their predictive accuracy, and thus of their clinical value, it is essential to perform a head-to-head comparison of all published prognostic models in one independent cohort. [19] [20] [21] Thus, the aim of our study was to perform external validation and direct head-to-head comparison of all published first trimester prognostic models for gestational diabetes mellitus, in one independent cohort.
Methods
study population of external validation cohort
We performed a large prospective multicentre cohort study (the Risk EStimation for PrEgnancy Complications to provide Tailored care (RESPECT) study) to validate prognostic models for gestational diabetes mellitus. From December 2012 to January 2014, we included pregnant women at their initial prenatal visit (<14 weeks of pregnancy) in 31 independent midwifery practices (primary care) and six hospitals (secondary or tertiary care) in the central region of the Netherlands. We excluded women with any type of pre-existing diabetes mellitus from the cohort. During their pregnancies, participants received routine antenatal care according to Dutch clinical guidelines.
This study was approved by the medical ethics committee of the University Medical Centre Utrecht (protocol no 12-432/C) and written informed consent was obtained from all participants. Results have been reported to conform with the TRIPOD statement. 22 23 Predictor assessment Predictors for gestational diabetes mellitus were all measured in the first trimester at the initial prenatal visit by caregivers or via a self-administered questionnaire. Supplementary appendix A provides detailed information on predictor definition and measurement. We did not report on the distributions of predictors among the original studies that we validated, because it was often missing in the original publications.
Outcome assessment
Gestational diabetes mellitus was diagnosed by a 75 g, two hour, oral glucose tolerance test between 24 and 28 weeks of gestation. According to the World Health Organization 1999 guidelines, which conform with the Dutch national recommendation, the disorder is indicated by the presence of either a fasting glucose level of at least 7.0 mmol/L (126 mg/dL) or a glucose level of at least 7.8 mmol/L (140 mg/dL) after two hours. 24 25 Women were offered an oral glucose tolerance test if risk factors or any signs of gestational diabetes mellitus were present. Without risk factors or signs, women were not tested and considered as not having gestational diabetes mellitus.
Body mass index in first trimester greater than 30, history of gestational diabetes mellitus, history of macrosomia (birthweight above 95th centile of the Dutch population), 26 family history of diabetes mellitus (first degree), non-western ethnicity, history of unexplained intrauterine fetal death, and polycystic ovary syndrome were considered as risk factors for gestational diabetes mellitus. Polyhydramnios and macrosomia were considered as possible signs of the disorder.
For studies validating prognostic models, there is no solid sample size recommendation, but a minimum of 100 patients with events and at least 100 patients without events has been suggested. 27 selection of prognostic models for external validation In a previous systematic review, we identified 14 published prognostic models for gestational diabetes mellitus that can apply to the first trimester of pregnancy and that only consist of routine measures that are easy to obtain (unpublished data). A short summary of this systematic review is provided in supplementary appendix B.
For proper external validation, it is preferable that the exact definitions of the predictors included in the 14 prognostic models under validation are known as well as how they were measured. Although five of the author groups of the publications of these prognostic models were contacted by email for additional information on intercepts, predictor weights (regression coefficients), and definitions of predictors in the model, none of them responded. Despite this lack of information, it was still possible to include four of these five models in our head-to-head validation study, leaving one model that had to be excluded owing to missing intercept and coefficients. 28 Moreover, we excluded one prognostic model from analysis for using maternal abdominal circumference and diagnosis of polycystic ovary syndrome as predictors, which we did not collect in our validation cohort and for which there was also no proxy variable available. 29 Thus, a total of 12 prognostic models remained for external validation in the current study. [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] Supplementary appendix C shows the equations of these 12 prognostic models as applied in our cohort. Table 1 30-41 also summarises predictors that were included in the prognostic models. None of the authors of the current external validation study was involved in the development of any of these models.
statistical analysis
Predictor and outcome information was missing for some patients in the validation cohort, and these data were not missing completely at random, as can be derived from table 2 . To avoid biased validation of the models, we imputed the missing values using multiple imputation. 42 All possible predictors and outcomes were used in the imputation model. Ten imputations were performed. Results shown are the results after the multiple imputed data, unless otherwise specified.
Firstly, we applied the original prognostic modelsthat is, exactly as they were published-to our study cohort when the full prediction rule, including its intercept, was available (supplementary appendix C). Next, to allow for fair comparison of the prognostic models, we performed logistic recalibration by fitting logistic regression models using the linear predictor as the only covariate. This step resulted in an updated calibration slope and intercept. 43 44 We assessed discrimination using Harrell's C statistic, which is equivalent to the area under the receiver operating characteristic curve. 45 It verifies whether participants with a higher predicted risk for gestational diabetes mellitus are indeed more likely to have the disease.
Calibration of the validated original and logistically recalibrated models was assessed by calculation of the predicted probabilities of gestational diabetes mellitus for each individual and comparison of these with their observed outcomes in calibration plots. When a model is well calibrated, the predicted probabilities equal the observed proportions for all groups of predicted probabilities. Thus, when a model is well calibrated, the calibration plot has an intercept of 0 and a slope of 1 and all groups (normally 10 groups) of predicted probabilities fit close to this line. Some calibration plots, however, have fewer than 10 points because it was not possible to split the predicted probabilities into 10 groups. This was the case for models that included only a few categorical variables (eg, sum score models) in which a limited number of predicted probabilities (<10) were possible.
The calibration intercept and slope of the linear prediction after recalibration were used to assess overestimation and underestimation of the models as well as overfitting. A calibration intercept of less than 0 indicates overestimation (the predictions from the original models are too high), whereas an intercept of greater than 0 indicates underestimation. A calibration slope of less than 1 indicates overfitting of the original prognostic models. 46 A history of gestational diabetes mellitus is an important predictor in most models, but is always scored as negative (=zero) in the prognostic algorithms for nulliparous women, owing to them not having had a previous pregnancy. Therefore, we also reassessed discrimination and calibration of all 12 logistically recalibrated models in a subgroup analysis of nulliparous women to see if the results of the whole population were not merely the result of an excellent prediction of gestational diabetes mellitus in multiparous women (that is, women with a known history of the disorder). Finally, decision curve analysis was performed for the prognostic models with the best discriminative abilities. 47 Such analyses provide insight into the range of predicted risks for which the model has a higher net benefit than simply either classifying all patients as having the outcome or no (zero) patients as having the outcome. Decision curve analysis can also compare the net benefits of models.
All analyses were done on each of the multiple imputed datasets, and Rubin's rules were used to combine the results into summary estimates. Analyses were performed by the mice and rms packages of R-3.1 for Windows (http://cran.r-project.org).
Patient involvement
The HELLP Foundation, a Dutch patient confederation for patients who had a pregnancy complicated by hypertensive disorders, was involved in defining the research question and the design of the study. Pregnant women were not involved in defining the outcome measures. Focus group interviews with pregnant women participating in the RESPECT cohort were organised to discuss the results and how these results should be implemented into routine care. The final results will be disseminated on the internet through the websites of midwifery practices and regional midwifery collaboration associations.
Results
resPeCt cohort
Of 3723 women included for analysis, 1655 (44%) were nulliparous (fig 1 ) . Table 2 shows the baseline characteristics of these women. Gestational diabetes mellitus was diagnosed in 181 (4.9%) women, 33 (18%) of whom needed insulin for glycaemic control. In the nulliparous subgroup, 71 women (4.3%) developed gestational diabetes mellitus. In four prognostic models (Gabbay-Benziv 2014, Nanda 2011, Naylor 1997, and Teede 2011), discrimination for nulliparous women was worse than that for the overall population (table 3 ) . For all other models, the C statistic was higher for nulliparous women only than for all women. Calibration of the prognostic models was also acceptable to good in the nulliparous subgroup (fig 4) .
Calibration of prognostic models
Decision curve analysis
The decision curve analysis results of the four most discriminating models (Gabbay-Benziv 2014, Nanda 2011, For predicted probability thresholds between 0% and 40%, either prognostic model showed a positive net benefit.
discussion
Principal findings
A total of 12 first trimester prognostic models for gestational diabetes mellitus were selected by comprehensive review of literature and were compared headto-head for their predictive accuracy in our population based cohort of 3723 women. Two prognostic models overall and Van Leeuwen 2010) had the best performance based on discrimination, calibration, and performance in nulliparous subgroup. Predictors in these particular prognostic models (that is, maternal age, body mass index, ethnicity, parity, history of gestation diabetes mellitus, and history of macrosomia) are easy to measure and widely applicable. Calibration was good for all models and improved by recalibration of the models to our population. Although obstetric history is an important predictor in most models, the prognostic models for gestational diabetes mellitus also performed well in nulliparous women.
strengths and limitations
This external validation study comprises almost all published, first trimester, prognostic models for gestational diabetes mellitus in one cohort study, allowing for head-to-head comparison of these models. Our study had a large sample size and many cases of gestational diabetes mellitus, used a prospective multicentre approach, and included an unselected population of women from primary care (low risk) as well as secondary or tertiary care (high risk) within a geographically defined area. Additionally, missing data were handled by multiple imputation, which is the most preferable method. 48 However, some limitations of our study need to be addressed. Firstly, according to Dutch guidelines, a high risk strategy was adhered. To prevent unnecessary testing in study participants, women without predefined risk factors only underwent an oral glucose tolerance test in case of any symptoms of gestational diabetes mellitus. This strategy could have led to an underestimation of the disorder in low risk women. A study on the performance of similar strategies estimated that 7.3% of diagnoses of gestational diabetes mellitus may have been missed. 49 However, this possible underestimation is unlikely to have affected the discriminative ability of the validated models, because the C statistic is a rank order insensitive to systematic errors in calibration such as differences in outcome incidence. 50 Moreover, this potential underestimation is also unlikely to have affected our inferences on the predictive accuracy of the models because we recalibrated the models, which accounts for any differences in overall incidence of gestational diabetes mellitus between the original model development studies and our external validation study. Thus, regardless of any known differences in disease incidence, it is important that prognostic models are recalibrated before they are applied to a new population or when different diagnostic criteria are used. Secondly, we were not able to include two published prognostic models in our external validation. For one model, information on the prediction rule was not available despite contacting the authors. The other study was published after the start of data collection for our validation cohort, and information on some predictors (such as maternal abdominal circumference and presence of polycystic ovary syndrome) was not collected.
Comparison with other studies
Validation studies on prognostic models for gestational diabetes mellitus are scarce. Our study differs from previous validation studies [15] [16] [17] [18] by performing a head-tohead comparison, whereas other studies validated a single prognostic model or only a small selection of the prognostic models for gestational diabetes mellitus. However, our findings are similar to those of these external validation studies, except for the external validation of the Van Leeuwen 2010 model by Lovati and colleagues. 15 In that study, the Van Leeuwen 2010 model yielded a poor C statistic (0.60), by contrast with the other external validation studies (including our current study) that showed C statistics between 0.74 and 0.77. 17 38 This difference might be due to the case-control study design chosen by Lovati and colleagues, in which it is not possible to adjust for observed outcome frequency.
Clinical implications and conclusions
The use of accurate first trimester prognostic models for gestational diabetes mellitus allows for early and personalised risk stratification in pregnancy. This approach is in contrast to current strategies in which an oral glucose tolerance test is either performed in all women [9] [10] [11] [12] or performed in the presence of any prespecified risk factors. 13 Prognostic models have the advantage of being cheap and easy to implement and could avoid the need to perform an oral glucose tolerance test in women with a low risk of developing gestational diabetes mellitus, which relieves both burden and costs. 9 10 A comparison of performance between the best discriminating prognostic models and current strategies allows an approach that weighs up the pros and cons (eg, missed cases), and will help choose the model to be implemented into clinical practice. The decision on which of the four best models to implement in clinical practice might also depend on population characteristics, availability of predictors, and the incidence of gestational diabetes mellitus, and could therefore be country or region specific. Implementation of prognostic models for gestational diabetes mellitus early in pregnancy provides room for preventive measures-that is, lifestyle modification interventions such as diet and exercise counselling. 51 52 Although drug treatments should probably not be the preferred primary intervention to prevent gestational diabetes mellitus, metformin could have a role in the prevention of the disorder in high risk populations. 53 54 Early prevention, screening, diagnosis, and treatment of gestational diabetes mellitus, when necessary, can and will most likely reduce the rates of caesarean section, neonatal hypoglycaemia and macrosomia, and long term neonatal complications. 4 In conclusion, most of the 12 previously published prognostic models for gestational diabetes mellitus that have been validated in this study show acceptable to good discrimination and calibration. Four models had C statistics of at least 0.75 (Gabbay-Benziv 2014, Nanda 2011, Teede 2011, and Van Leeuwen 2010). We recommend that these four models be further investigated for implementation in clinical practice. The models by Teede and colleagues and Van Leeuwen and colleagues, with the best overall performance, are easy to apply in clinical practice. The models consist of straightforward predictors: maternal age, body mass index, ethnicity, parity, history of gestational diabetes mellitus, and history of macrosomia. Once prognostic models for gestational diabetes mellitus are applied in routine clinical care, further research is recommended on the effects on clinical impact, actual development of the disorder, and subsequent pregnancy outcomes.
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